238 related articles for article (PubMed ID: 35094801)
1. Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review.
Jiao B; Basu A; Ramsey S; Roth J; Bender MA; Quach D; Devine B
Value Health; 2022 Feb; 25(2):276-287. PubMed ID: 35094801
[TBL] [Abstract][Full Text] [Related]
2. Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease.
Jiao B; Hankins JS; Devine B; Barton M; Bender M; Basu A
Qual Life Res; 2022 Sep; 31(9):2729-2738. PubMed ID: 35715626
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
4. Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?
Ara R; Hill H; Lloyd A; Woods HB; Brazier J
Value Health; 2020 Mar; 23(3):397-405. PubMed ID: 32197736
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of health-state utilities used in cost-effectiveness analyses: a systematic review of published studies in Asia.
Yang Z; Zeng X; Huang W; Chai Q; Zhao A; Chuang LH; Wu B; Luo N
Health Qual Life Outcomes; 2023 Jun; 21(1):59. PubMed ID: 37340446
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
7. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
9. Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report.
Brazier J; Ara R; Azzabi I; Busschbach J; Chevrou-Séverac H; Crawford B; Cruz L; Karnon J; Lloyd A; Paisley S; Pickard AS
Value Health; 2019 Mar; 22(3):267-275. PubMed ID: 30832964
[TBL] [Abstract][Full Text] [Related]
10. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease.
Darbari DS; Hampson JP; Ichesco E; Kadom N; Vezina G; Evangelou I; Clauw DJ; Taylor Vi JG; Harris RE
J Pain; 2015 Nov; 16(11):1077-86. PubMed ID: 26291276
[TBL] [Abstract][Full Text] [Related]
12. The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature.
Jiao B; Basu A; Roth J; Bender M; Rovira I; Clemons T; Quach D; Ramsey S; Devine B
Pharmacoeconomics; 2021 Nov; 39(11):1225-1241. PubMed ID: 34368937
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Association Between Health State Utilities and Obesity in Sub-Saharan Africa: Evidence From World Health Organization Study on Global AGEing and Adult Health Wave 2.
Lartey ST; Si L; de Graaff B; Magnussen CG; Ahmad H; Campbell J; Biritwum RB; Minicuci N; Kowal P; Palmer AJ
Value Health; 2019 Sep; 22(9):1042-1049. PubMed ID: 31511181
[TBL] [Abstract][Full Text] [Related]
14. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
15. Sickle Cell Disease: A Review.
Kavanagh PL; Fasipe TA; Wun T
JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
[TBL] [Abstract][Full Text] [Related]
16. Health state utilities for economic evaluation of bariatric surgery: A comprehensive systematic review and meta-analysis.
Xia Q; Campbell JA; Ahmad H; Si L; de Graaff B; Otahal P; Palmer AJ
Obes Rev; 2020 Aug; 21(8):e13028. PubMed ID: 32497417
[TBL] [Abstract][Full Text] [Related]
17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
18. Association between knee symptoms, change in knee symptoms over 6-9 years, and SF-6D health state utility among middle-aged Australians.
Singh A; Campbell JA; Venn A; Jones G; Blizzard L; Palmer AJ; Dwyer T; Cicuttini F; Ding C; Antony B
Qual Life Res; 2021 Sep; 30(9):2601-2613. PubMed ID: 33942204
[TBL] [Abstract][Full Text] [Related]
19. Differences in quality of life between pediatric sickle cell patients who used hydroxyurea and those who did not.
Nwenyi E; Leafman J; Mathieson K; Ezeobah N
Int J Health Care Qual Assur; 2014; 27(6):468-81. PubMed ID: 25115050
[TBL] [Abstract][Full Text] [Related]
20. New therapies and approaches to transfusion in sickle cell disease in children.
Styles LA; Vichinsky EP
Curr Opin Pediatr; 1997 Feb; 9(1):41-5. PubMed ID: 9088754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
